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Abstract
Objectives: The overall aim of this study is to discern whether and to what degree vaccination sites
exhibit constant returns to scale.
Methods: Data Envelopment Analysis is used to compare all the facilities in the sample in terms of
input costs used to produce multiple outputs. The application considers the Expanded Program on
Immunization (EPI), which operated in Dhaka City, Bangladesh, during 1999.
Results: A preponderance of EPI sites were determined to be operating at increasing returns to scale.
Conclusions: Our findings question the applicability of cost-effectiveness analyses that assume con-
stant returns to scale.
Keywords: Scale, Efficiency, Immunization, Data envelopment analysis, Bangladesh
Compared with other health interventions, vaccinations are judged to be one of the most
cost-effective ways of improving and maintaining child health, especially in low-income
countries (16). This view has been held for a considerable time (e.g., 15) and may help
to explain the increase in global coverage of the Expanded Program of Immunization
(EPI) from an average of 5 percent at its inception in 1974 to the current average of
80 percent (4). Many cost and cost-effectiveness analyses of EPI country programs in low-
income countries have been evaluated at a given level of production (e.g., 11), used only
a few providers (e.g., 4), or aggregated and averaged at a country level (e.g., 1;14). Even
when studies estimated the costs of increasing coverage rates or predicted country-wide
estimates of costs from a small study, most have assumed a linear function to “scale-up”
programs (10). For example, if the unit cost per fully vaccinated child is $20, the increase
in expanding vaccination services for another fifty children is assumed to be $1,000.
That such constant returns to scale exist is doubted. For example, England et al. (5) have
hypothesized that many impediments exist to scaling up measles control in West and Central
Africa and suggested that considerable investment would be needed in management and
health systems before expansion. In reviewing the cost profiles of immunization programs
from accounting-based cost studies, some investigators have found that the proportion of
fixed costs indicates the likely existence of economies of scale (e.g., 8).
If average costs and incremental cost-effectiveness ratios did change with production,
then assuming constant returns to scale would produce biased estimates of any change
in production, and the bigger the expected change, the larger the bias. Even if size were
accounted for, there is no notion of best practice benchmarking (2) or knowledge of how
this might change by setting. In this study, both of these issues are addressed by a novel
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application of data envelopment analysis. Three objectives are pursued: first, the cost of
delivering routine vaccination services from the perspective of the providers is determined;
second, the outputs of vaccination sites for each provider in terms of the number of doses of
each type of vaccine is assessed; third, the scale efficiency of the vaccination sites as well
as factors that explain variation in scale efficiency are evaluated.
THE BANGLADESH EPI
The EPI in Bangladesh was established in 1979 and became fully operational in 1985. It
aimed to reduce morbidity and mortality from six vaccine-preventable diseases. Therefore,
a fully vaccinated child received six standard EPI antigens against diphtheria, pertussis, and
tetanus (DPT), tuberculosis (TB), polio, and measles through eight vaccinations. Pregnant
women were also given vaccinations to prevent maternal and neonatal tetanus. Since 1985,
vaccination coverage has increased from 2 percent for all antigens to a reported 92 percent
for BCG and 62 percent for measles (16). However, immunization coverage rates were much
lower in urban compared with rural areas. Therefore, in 1988, the United States Agency for
International Development implemented a program to strengthen vaccination services in
urban areas in conjunction with the array of government and nongovernment funders and
providers of service.
METHODS
Data envelopment analysis (DEA) was used to allow comparison of all the clinics in the
sample in terms of input costs used in the production of multiple outputs. DEA is a nonpara-
metric, deterministic approach using linear programming techniques that defines a “best
practice” production frontier. Firms lying on the production frontier are considered to be
operating at the best practice or in other words, provide a benchmark a` la Birch and Gafni
(2). However, it should be noted that the measure of efficiency is considered to be rela-
tive rather than absolute, as no a priori information exists as to what should be considered
as absolute efficiency. The benchmark clinics, that is, those that are technically and scale
efficient, reflect the best practice for the given sample of clinics.
A benefit of this DEA approach is that, by identifying best practice by a “local” standard,
it may be assumed that given certain productive characteristics (as well as environmental
ones) best practice can be feasibly reproduced at the less-efficient clinics. Another benefit
of the DEA approach used here is that the overall technical efficiency (TECRS) measure can
be decomposed into pure technical efficiency (TEVRS) and scale efficiency (SE). In other
words, TECRS = TEVRS × SE.
Whereas there have been a plethora of other related studies applying DEA to the health
care sector using quantities of inputs in their natural units to produce outputs (see 13 for
a review), we specified the objective as minimizing input costs given outputs (6;7). As the
objective of this study is to determine scale effects, the definition of the cost minimizing
technology used here was applicable.
The technology was initially constructed under constant returns to scale and strong
disposability of costs (as costs increase, outputs must increase, ceteris paribus) TECRS.
Allowances can be made in the restraints to allow for variable returns to scale TEVRS.
Furthermore, we determined the type of scale inefficiencies by using a third model TENIRS.
In all these cases, we followed the definitions given by Fa¨re, Grosskopf, and Lovell (7) and
solved similar linear programming problems. We used the DEAP program by Coelli (3) for
the computations.
The technology is said to be operating at a cost- as well as scale-efficient level if
TECRS = TEVRS. However, if they were not equal, the extent to which inefficiency was caused
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due to operating at the wrong scale was assessed. Determining the type of scale inefficiency
(either increasing or decreasing returns to scale) required the solution of a third linear
programming problem, referred to as nonincreasing returns to scale technology (NIRS).
To define the type of scale inefficiency that is operating here, we compared the solutions
of the three linear programming problems. If TECRS
TEVRS
< 1, TECRS = TENIRS then increasing
returns to scale exist. If TECRS
TEVRS
< 1, but, TENIRS > TECRS, then decreasing returns to scale
exist. Such models allowed for the impact of scale effects on the EPI clinics to be evaluated.
However, deviations from the best practice frontier may be due to independent factors
that may be out of the managers’ or policy makers’ direct control. Therefore, the measures
of efficiency were analyzed by using a variety of statistical tests, in conjunction with other
environmental factors that may affect scale efficiency.
DATA AND RESULTS
Our sample was obtained by means of a 1999 cost analysis of EPI services undertaken
in a random sample of 25 percent of the facilities (132 of 511) providing EPI services in
Dhaka City Corporation. To be parsimonious, five outputs (the amount of doses given for
DPT, TB, polio, measles, and TT in 1999) and one input (total program costs of the EPI
by site) were specified. Only program sites with full information were included. The final
data set consisted of 117 of a possible 132 total clinics. Hence, 89.3 percent of all clinics
sampled were included. The type of missing data that resulted in sites being excluded from
the sample included ownership form, type of vaccination site, duration of operation, as well
as some of the outputs. The descriptive statistics are given in Table 1.
Turning next to our efficiency results given in Table 2, we found that overall efficiency
(TE CRS) was only 0.33. In other words, if program sites were technically efficient and
operated at the correct scale, costs on average could have been reduced by 67 percent without
sacrificing the current level of outputs produced. By decomposing this overall measure into
pure technical efficiency (TE VRS) and scale efficiency, we found that more of the overall
inefficiency was due to sites incurring too much cost in producing the array of vaccinations
rather than operating at the wrong size. However, both sources of this overall inefficiency
must be addressed for these sites to become less wasteful of scarce resources.
Given the findings that the sites in this sample exhibited variable returns to scale, the
types of diseconomies of scale were examined next. Table 3 shows that the majority of
the program sites exhibited increasing returns to scale (suggesting that they are too small),
17 program sites exhibit decreasing returns to scale (suggesting that they are too large), and
only six program sites were the “right” size.
In Tables 4 and 5, we assessed whether differences in efficiency followed systematic
patterns due to factors beyond managerial control. Table 4 displays statistically significant
differences between the efficiency of two ownership forms, and shows that scale efficiency
is relatively greater in government-owned program sites. As outreach sites were statistically
significantly less scale efficient than fixed sites, we infer that satellite sites are too small
given the best practice frontier.
Although the EPI program has been in existence in Dhaka City Corporation since 1988,
not all sites began providing EPI services at the same time. Table 5 shows that the length
of time a program site has been in operation is positively correlated with scale efficiency.
DISCUSSION/POLICY IMPLICATIONS
The sites in our sample were, on average, relatively inefficient both in terms of technical
inefficiency as well as scale inefficiency. To become technically efficient, program sites
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Table 1. Descriptive Statistics of Outputs and the Inputs
Variable Mean SD Min Max
BCG 257.40 304.94 1 1,680
DPT 578.57 685.54 1 3,264
Polio 707.42 842.91 1 3,756
Measles 190.28 210.83 1 960
TT 390.03 443.37 1 2,208
Total costs 2,600.31 4,972.79 238 45,716
Table 2. Descriptive Statistics of Efficiency Measures
Measure Mean SD Min Max
TE CRS 0.33 0.26 0.001 1.00
TE VRS 0.50 0.29 0.012 1.00
Scale 0.64 0.27 0.007 1.00
Table 3. Returns to Scale in Vaccination Sites
Types of returns to scale Number of vaccination sites
Increasing 95
Constant 6
Decreasing 17
Table 4. Selected Statistics between Ownership and Type of Clinics and Efficiency
Mean Scale F-test Median test Kruskal-Wallis
efficiency score (p > F) (p > Z) (p > χ2)
Government (N = 25) 0.77
NGO (N = 92) 0.60 8.82 (.003) 2.47 (.01) 9.77 (.002)
Fixed (N = 35) 0.79
Outreach (N = 82) 0.57 19.73 (.0001) 3.81 (.0001) 17.80 (.0001)
NGO, not government owned.
Table 5. Correlation Coefficients for Time Since EPI Clinic Opened and Total Cost and Scale
Variables Correlation coefficient p > |r |
Time/scale 0.34 (.0001)
Total costs/scale 0.16 (.08)
EPI, Expanded Program on Immunization.
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would have had to decrease their costs by an average of 50 percent, and if they had been
operating at the right size, costs could have been reduced by a further 36 percent. Sites
that were relatively more inefficient, on average, were not government-owned satellites.
Therefore, the governmentally owned sites, perhaps due to more centralized control, ap-
peared to be better at long-term planning. We also found that sites that had been practicing
longer were relatively more scale efficient, which is perhaps attributable to a learning curve
effect.
The presence of pure technical inefficiencies suggests that, if such cost data were used
as the numerator of a cost-effectiveness ratio, a cost-effectiveness analysis would not reflect
the minimum efficient point of production at a given level. However, to ascertain whether
this outcome is likely to be the case, researchers need to begin using a larger sample size of
provider units for costing, especially if results are intended for use beyond the geographical
focus of an evaluation.
Our evidence provides empirical support to Jacobs and Baladi’s (9) contention that
assuming constant returns to scale might not be realistic. The presence of increasing returns
has two particular implications. First, that this intervention cannot be treated as perfectly
divisible within a population and retain the same level of incremental cost-effectiveness.
Second, it suggests that, if constant returns to scale are assumed when increasing returns to
scale exist, an intervention is likely to be overprovided in that form. Finally, the potential
learning effect raises questions about how relevant it is to transfer cost-effectiveness ratios
over time or across countries as levels of technology differ (12). Therefore, we conclude
that ignoring the possible existence of technical inefficiencies and variable returns to scale
would make the generalizability of cost-effectiveness ratios suspect and could worsen rather
than improve the allocation of resources.
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